The Potential Application of *Spirulina* (*Arthrospira*) as a Nutritional and Therapeutic Supplement in Health Management

Amha Belay, PhD*
Scientific Director, Earthrise Nutritionals Inc., Calipatria, California
The Potential Application of
Spirulina (Arthrospira) as a Nutritional and Therapeutic Supplement in Health Management

Amha Belay, PhD*
Scientific Director, Earthrise Nutritionals Inc., Calipatria, California

INTRODUCTION

Spirulina, now named Arthrospira, is a microscopic and filamentous cyanobacterium (blue-green alga) that has a long history of use as food. Its name derives from the spiral or helical nature of its filaments (Fig 1). There are reports that it was used as food in Mexico during the Aztec civilization some 400 years ago. It is still being used as food by the Kanembu tribe in the Lake Chad area of the Republic of Chad where it is sold as dried bread called “dihe”.1 Spirulina has been produced commercially for the last 20 years for food and specialty feeds.2-4 Commercial algae are normally produced in large outdoor ponds under controlled conditions (Fig 2). Some companies also produce directly from lakes. Current production of Spirulina worldwide is estimated to be about 3,000 metric tons. Sold widely in health food stores and mass-market outlets throughout the world, Spirulina’s safety as food has been established through centuries of human use and through numerous and rigorous toxicological studies.5-8

Early interest in Spirulina focused mainly on its rich content of protein, vitamins, essential amino acids, minerals, and essential fatty acids. Spirulina is 60-70% protein by weight and contains a rich source of vitamins, especially vitamin B12 and provitamin A (β-carotene), and minerals, especially iron. One of the few sources of dietary γ-linolenic acid (GLA), it also contains a host of other phytochemicals that have potential health benefits.

The objectives of this paper are 1) to review the available literature on the potential health effects of Spirulina and its extracts, 2) to provide insight into the potential implications of the studies reviewed in the context of possible nutritional and therapeutic applications in health management, and 3) to identify areas of interest for future research.

IMMUNOMODULATION EFFECTS

In a 1993 review of the potential health benefits of Spirulina, Belay et al.9 presented the limited published information on this alga and called the attention of researchers to the particular areas of immune enhancement and cancer. Numerous studies have been published since then. The evidence for immune modulation of Spirulina in various animal models is so striking that structure function claims have already been applied to some Spirulina products.

A summary of the major studies on immunomodulation properties of Spirulina is given on Table 1.

Hayashi et al.10 were the first to publish detailed studies on immunomodulatory properties of dietary Spirulina in mice. According to their results, 1) mice fed Spirulina showed increased numbers of splenic antibody-producing cells in the primary immune response to sheep red blood

* Correspondence:
Amha Belay, PhD
Earthrise Nutritionals Inc.
P.O. Box 270, Calipatria, CA 92233
Phone: 760-348-5027 Fax: 760-348-7258
Email: abelay@cts.com
Table 1. Summary of studies in immunomodulation

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Summary of Studies</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>Increased numbers of splenic antibody-producing cells in the primary immune response to sheep red blood cells (SRBC).</td>
<td>10, 11</td>
</tr>
<tr>
<td>In vitro</td>
<td>The percentage of phagocytic cells in peritoneal macrophages was significantly increased. The proliferation of spleen cells by either concavalin A (Con A) or phytohemagglutinin (PHA) was significantly increased. Hot water extract of <em>Spirulina</em> (SHV) significantly increased proliferation of spleen cells. Hot water extract significantly enhanced interleukin-1 (IL-1) production from peritoneal macrophages. Hot water extract enhanced the production of antibodies by spleen cells and macrophage supernatants.</td>
<td>10</td>
</tr>
<tr>
<td>In vitro</td>
<td><em>Spirulina</em>-treated chicken macrophages showed increased spreading and vacuolization with minimal cytotoxicity. Higher percentage of phagocytic macrophages for unopsonized SRBC; higher number of internalized SRBC.</td>
<td>12</td>
</tr>
<tr>
<td>Chicken</td>
<td>Significant improvement in PHA-P-induced toe web swelling (CBH assay) at levels of 1,000 ppm and beyond. Increased T-cell proliferation. <em>Spirulina</em> supplementation (1,000 ppm) resulted in an almost complete <em>E. coli</em> clearance from blood circulation 30 minutes post injection.</td>
<td>14</td>
</tr>
<tr>
<td>Chicken</td>
<td>Increased size of thymi. Higher anti-red blood cell antibody titers in the secondary response especially at the higher supplementation (10,000 ppm). Higher PHA-P-mediated lymphoproliferative response especially at 10,000 ppm supplementation. Higher phagocytic potential and NK cell activity in macrophages isolated from the K-strain and broiler chicks.</td>
<td>16</td>
</tr>
<tr>
<td>In vitro</td>
<td>Increased phagocytic potential of cat bronchoalveolar lavage macrophages exposed to water extract of <em>Spirulina</em>.</td>
<td>17</td>
</tr>
<tr>
<td>Channel catfish</td>
<td>Peritoneal phagocytes from fish fed <em>Spirulina</em> enhanced phagocytosis to zymosan and chemotaxis to <em>E. ictaluri</em> exocantigen.</td>
<td>18</td>
</tr>
<tr>
<td>Prawns</td>
<td>The activity of granulocytes and hyaline cells was enhanced significantly in tiger prawns (<em>Peneaus monodon</em>) supplied with a feed containing as low as 0.1% (w/w) dry <em>Spirulina</em>.</td>
<td>19</td>
</tr>
</tbody>
</table>
Table 1. Summary of studies in immunomodulation (continued)

<table>
<thead>
<tr>
<th>Model</th>
<th>Treatment</th>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prawns</td>
<td>Prawns fed with <em>Spirulina</em> could clear <em>Vibrio parahaemolyticus</em>, a pathogen of prawns, from the hemolymph at half the time taken by control prawns fed with basal diet.</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>In vitro</td>
<td>In human peripheral blood mononuclear cells (PBMC), <em>Spirulina</em> stimulated the secretion of Interlutin (IL-1b), IL-4 and interferon (IFN)-γ to nearly 2.0, 3.3, and 13.6 times basal levels, respectively; much higher ratio of IFN-γ to IL-4 favoring cellular immunity.</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Human</td>
<td>IFN-γ secretion activity and NK-cell cell damage activities were enhanced significantly after two weeks of administration of <em>Spirulina</em> extract to 40 year-old male volunteers. IFN-γ and NK cell activities continued up to 6 months after the administration of extract was discontinued.</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Mice</td>
<td>Co-administration of <em>Spirulina</em> hot water extract with a cell wall component obtained from <em>Tubercle bacillus</em> (BCG-CWS) resulted in a much higher tumor regression in tumor-bearing mice than with BCG-CWS alone. A 93% reduction in tumor progression in the combined BCG-CWS and <em>Spirulina</em> hot water extract treatment compared to about 48% in the group that received BCG-CWS alone.</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Human</td>
<td>The above-normal IgE levels observed in 35 preschool children living in highly radioactive areas were normalized by the administration of 5 grams of <em>Spirulina</em> a day for 45 days.</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Rats</td>
<td><em>Spirulina</em>-inhibited compound 48/80-induced anaphylactic shock 100% with doses of 0.5, and 1.0 mg/g body weight. Significant reduction in serum histamine levels induced by compound 48/80. Passive cutaneous anaphylaxis activated by anti-dinitrophenyl (DNP) IgE was inhibited to 69% <em>Spirulina</em> dose-dependently inhibited histamine release from rat peritoneal mast cells (RPMC) by compound 48/80. <em>Spirulina</em> had a significant effect on the anti-DNP IgE-induced histamine release or tumor necrosis factor-α production from RPMC.</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Rats</td>
<td>Anti-inflammatory effect (reduction in MPO activity) and inhibition in inflammatory cell infiltration by phycocyanin.</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Mice</td>
<td>IgE antibody levels increased in the mice that were orally immunized with crude shrimp extract as an antigen.</td>
<td>27</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Summary of studies in immunomodulation (continued)

<table>
<thead>
<tr>
<th>Prawns</th>
<th>Human</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Spirulina</strong> had no additional effect on the IgE level when it was administered with the antigen. Co-administration of Spirulina with the antigen further enhanced the level of IgG1 in excess of the level found by antigen administration only. IgA antibody level was significantly enhanced by treatment with Spirulina extract concurrently ingested with shrimp antigen compared with the level with shrimp antigen alone.</td>
<td>Significant correlation between the total s-IgA level in the saliva and the total amount of Spirulina consumed.</td>
</tr>
</tbody>
</table>

Qureshi et al. did similar studies where sephadex-elicited macrophage cultures were exposed to a 10-40 µg/ml (v/v) water-soluble extract of Spirulina for 1-16 hours. They found the following: 1) Spirulina-treated macrophages showed increased spreading and vacuolization with minimal cytotoxicity, 2) the percentage of phagocytic macrophages for unopsonized sheep red blood cells (SRBC) and average number of internalized SRBC was higher in the Spirulina-treated macrophages compared to controls, and 3) culture supernatants from Spirulina-treated macrophages contained a factor with tumoricidal potential similar in reactivity to one produced by macrophages after treatment with lipopolysaccharides. Their results support earlier findings by Baojiang et al.

Qureshi’s group also studied Cutaneous Basophilic Hypersensitivity Response (CBH) and bacterial clearance potential in chicks (B15 B15, Cornell K-strain) fed a Spirulina supplement diet. CBH was studied by measuring toe web swelling after the injection of PHA-P. Toe web swelling is here used as an index of T-cell proliferation. A significant improvement was observed in PHA-P-induced peak response in chicks fed Spirulina at levels of 1,000 ppm and beyond. It was concluded that Spirulina supplementation improved T-cell-mediated response in chickens.

Also studied was the effect of Spirulina supplementation on blood clearance profile and splenic bacterial load. Leghorn chicks fed a diet containing 1,000 ppm of Spirulina exhibited numerically reduced bacterial load in both circulation and spleen. Spirulina supplementation at 1,000 ppm showed an enhanced E. coli clearance from blood circulation reaching almost negligible levels 30 minutes post injection. The effect was ascribed to improvement in the activity of phagocytic cells as reported in their earlier study. According to the authors, the reduction of viable bacteria in spleen tissue over time is suggestive of an immunopotentiating effect of a particular dietary compound on mononuclear phagocytic system cells. The antibacterial effect of macrophages activated by Spirulina has also been reported elsewhere.

In another study involving Cornell K-strain White Leghorn and broiler chicks, Qureshi et al. found that K-strain chicks had larger thyms over controls. They also found high anti-red-blood-cell antibody titers in the secondary response, especially at the higher supplementation group (10,000 ppm) compared to the control group (0 ppm). Chicks in the 10,000 ppm Spirulina group also had higher PHA-P-mediated lymphoproliferative response over the controls. Macrophages isolated from both K-strain and broiler chicks had higher phagocytic potential and NK cell activity. The authors concluded that a dietary inclusion of Spirulina at a level of 10,000 ppm might enhance disease resistance potential in chickens. Qureshi’s group did similar studies with cat macrophages exposed to Spirulina extract. They found increased phagocytic potential using red blood cells and E. coli.

In a study involving the effect of Spirulina in channel catfish (Ictalurus punctatus), Duncan and Klesius found that fish fed Spirulina had a lower percentage of erythro-
cytes and a higher percentage of lymphocytes than fish fed a control diet. There was no difference in thrombocytes and macrophages in the *Spirulina* and control diet. However, peritoneally-elicited phagocytes from fish fed *Spirulina* showed enhanced phagocytosis to zymosan and increased chemotaxis to *Edwardsiella ictaluri* exoantigen (5.9 times). *Spirulina* also enhanced production of antibodies to keyhole limpet hemocyanin (KLH) but not to *E. ictaluri*. Their results are similar to those by Hayashi et al. who showed in mice that *Spirulina* increased the antibody response to a thymus-dependent antigen but not to a thymus-independent antigen. In a similar study by Lee the activity of granulocytes and hyaline cells was enhanced significantly in tiger prawns (*Penaeus monodon*) with basal diet.

A group of researchers from University of California-Davis reported in 2000 the results of a study that adds evidence for the immunomodulatory effects of *Spirulina*. Using human peripheral blood mononuclear cells (PBMC), they demonstrated that *Spirulina* stimulated the secretion of Interlukin (IL)-1β, IL-4, and interferon (IFN)-γ to nearly 2.0, 3.3, and 13.6 times basal levels, respectively. Induction of (IFN)-γ by *Spirulina* was found to be comparable to that seen after phytohemagglutinin (PHA) stimulation while being much less mitogenic than PHA in the induction of IL-4. The preponderance of (IFN)-γ over IL-4 is believed to show that *Spirulina* is more effective in stimulating a Th-1-type response and hence potentiates cell-mediated immunity. The moderate stimulation of the production of IL-4, that may be due to the antagonistic activity of IFN-γ on IL-4, may mean that *Spirulina* helps balance the production of Th-1 and Th-2 cytokines. Thus *Spirulina* may provide strong protection against intracellular pathogens and parasites, and may also be effective in fighting extracellular parasites.

In a paper presented at the 30th annual meeting of the Japanese Society for Immunology, Saeki et al. presented the results of a human study using *Spirulina* extract. The immune modulation property of the extract in 40-year-old male volunteers was investigated using IL-12/IL-18-dependent IFN-γ secretion induction activity and cell damage activity by NK cell as indices. 50 ml of a commercial *Spirulina* drink (Dainippon Ink & Chemicals, Inc.) containing 40% *Spirulina* hot water extract was administrated to over 40-year-old male volunteers every day, and the IL-12/IL-18-dependent IFN-γ secretion induction activity of lymphocytes was chronologically analyzed by ELISA. Natural killer cell damage activity in blood was analyzed simultaneously. The analyses of the above parameters were done before and after administration of the extract. IFN-γ secretion activity and NK cell damage activities were enhanced significantly after two weeks of *Spirulina* extract administration. Surprisingly, the IFN-γ and NK cell activities continued up to 6 months after administration of extract was discontinued.

In another study reported at the 59th annual meeting of the Japanese Cancer Association, the same group, Saeki et al., reported the results of an investigation on the adjuvant effect of a hot water extract of *Spirulina* in the regression of tumors in tumor-bearing mice. Co-administration of *Spirulina* hot water extract with a cell wall component obtained from *Tubercle bacillus* (BCG-CWS) resulted in a much higher tumor regression in tumor-bearing mice than with BCG-CWS alone or in the untreated control mice. In this study BCG-CWS was administered in the mice, which were then immunized with inactivated B-16 melanoma. Following this, active melanoma cells were implanted subcutaneously. It is believed that microbial cell wall components like BCG-CWS act as inducers of dendritic cells, which play a major role in the induction of tumor-specific cytotoxic T-lymphocytes (CTL). The latter are believed to target high MHC-expressing tumor cells but fail to attack low MHC-expressing cells that are eliminated by natural killer cells. Since *Spirulina* has been found to be an effective activator of NK cells in previous studies, they suggested that this suppression of attack by CTL cells was probably killed by NK cells. Thus both BCG-CWS and *Spirulina* extract effectively controlled the tumor. The combined administration of BCG-CWS and *Spirulina* extract resulted in more than 90% regression.

The effect of *Spirulina* or its extracts on allergic reactions caused by food and other factors has been the subject of research recently. According to a Russian patent, the above-normal IgE levels observed in children in highly radioactive areas were normalized by the administration of 5 grams of *Spirulina* a day for 45 days. The level of IgE in the blood was taken as an index of allergy. The study was conducted with 35 preschool children living constantly in highly radioactive environments. (2-5 kv km²).

Yang et al. did extensive studies on the effect of orally-administered *Spirulina* on anaphylactic reaction. The following is a summary of their findings: 1) *Spirulina* inhibited compound 48/80-induced anaphylactic shock 100% with doses of 0.5 and 1.0 mg/g body weight, 2) *Spirulina* significantly reduced serum histamine levels induced by compound 48/80 in rats, 3) passive cutaneous anaphylaxis activated by anti-dinitrophenyl IgE was inhibited to 69%, 4) *Spirulina* dose-dependently inhibited histamine release from rat peritoneal mast cells by compound 48/80, and 5) *Spirulina* had a significant effect on the anti-DNP IgE-induced histamine release or tumor necrosis factor α production from RPMC. The authors postulate that the effects observed are possibly due to inhibition of anaphylactic degradation of mast cells by *Spirulina*.
Subsequent studies by Kim et al. on the effect of *Spirulina* on mast-cell-mediated immediate-type allergic reactions in rats also showed similar results. In this study *Spirulina* dose-dependently inhibited the systemic allergic reaction induced by compound 48/80 in rats. Compound 48/80-induced allergic reaction was inhibited 100% with intraperitoneal doses of 100-1,000 µg/g body weight. In rats treated with intraperitoneal dosages of *Spirulina* at concentrations ranging from 0.01 to 1,000 µg/g body weight, serum histamine levels were reduced in a dose-dependent manner. *Spirulina* also dose-dependently inhibited histamine release from rat peritoneal cells activated by compound 48/80 or anti-DNP IgE. *Spirulina* also had a significant inhibitory effect on anti-DNP IgE-induced tumor necrosis factor α production.

In a similar study published in 1999, Gonzalez et al. reported anti-inflammatory activity of phycocyanin extract in acetic-acid-induced colitis in rats using myeloperoxidase activity and histopathological and ultrastructural observations. Phycocyanin substantially reduced myeloperoxidase activity, and histopathological studies showed inhibition in inflammatory cell infiltration. The protection against inflammation was believed to be due to antioxidative and oxygen scavenging properties of phycocyanin.

Hayashi et al. investigated the influence of dietary *Spirulina platensis* on different classes of antibodies, including IgA, IgE, and IgG1 in mice as possible evidence of the protective effect of *Spirulina* toward food allergy and microbial infection. IgE antibody levels increased in mice orally immunized with crude shrimp extract as an antigen (Ag group). *Spirulina* had no additional effect on the IgE level when administered with the antigen. However, co-administration of *Spirulina* with the antigen enhanced the level of IgG1 in excess of the level found by antigen administration only. IgA antibody level was significantly enhanced by treatment with *Spirulina* extract concurrently ingested with shrimp antigen compared with the level of shrimp antigen alone. In mice treated with *Spirulina* for 4 weeks before antigen stimulation, an enhancement of IgA was observed in lymphoid cells, especially in the spleen and the mesenteric lymph node.

More recently, Ishii et al. studied the influence of *Spirulina platensis* on IgA levels in the saliva of 127 human subjects. Their results showed that total s-IgA levels were significantly higher when the subjects took *Spirulina* for over a year compared to those who took *Spirulina* for less than a year. They also found a significant correlation between the total s-IgA level in the saliva and the total amount of *Spirulina* consumed.

**IMPLICATIONS OF THE RESULTS OF THE STUDIES**

Our immune systems are our defense against pathogenic organisms like bacteria, viruses, cancer cells, and parasites, and against a whole series of compounds that are recognized as “foreign” or “non-self”. Any cell or molecule recognized as non-self is attacked by immune system cells and the antibodies they produce. The immune system is a complex system that involves specialized cells that communicate with each other via chemical messengers called cytokines. The immune system is also intricately tied up with the nervous and endocrine systems. Hence, impairment of the immune system has far-reaching consequences in the body.

It is now well established that nutrient deficiency is associated with consistent changes in immune responses such as number of T-cells, lymphocyte response to mitogens and antigens, phagocyte function, secretory IgA antibody response, compliment activity, NK cell activity, and production of cytokines. Nutrient excesses are also associated with impaired immune function. For example, dietary intake of large quantities of fats impairs immune response. In addition, the immune system can be positively or negatively affected by certain phytochemicals found in conventional foods and foods derived from other plants like algae, mushrooms, and some herbs.

The findings of the studies summarized above are significant in the context of natural and nutritional therapeutic intervention in the prevention of infection by pathogenic organisms. Non-specific cell-mediated immunity of the type found in these studies is the first line of defense against invading organisms. Enhancement of this aspect of the immune system will therefore have far-reaching advantages in body defense. Moreover, *Spirulina* appears to have a balancing effect on important immune cells and cytokines. Although cytokine-induced responses are generally protective in nature, an excess production and/or activity of cytokines can be harmful. It is known that the body possesses an elaborate system of checks and balances to control the production and activity of individual cytokines and that this process requires proper nutrition. *Spirulina* may provide such a nutritional role in modulating immune system function favorably.

The role of *Spirulina* in the activation of INFγ and NK cells observed in the human clinical study and the adjuvant effect seen in the regression of implanted mouse tumors are important in relation to the potential nutritional and therapeutic use of *Spirulina* in cancer immunotherapy. The anti-allergy effects observed in these studies are also significant in relation to natural therapeutic intervention in allergic situations. *Spirulina* neither induced nor enhanced allergic reactions dependent on IgE. On the contrary, it was found to enhance IgA production when ingested both concurrently with antigen and before antigen stimulation, providing protection against allergic reactions. The observation that secretory IgA production was found to correlate with *Spirulina* consumption may point to the potential role of *Spirulina* in mucosal immunity. The salivary glands are recognized as part of the common mucosal immune system,
and saliva is commonly used to study the effect of various parameters on the human mucosal immune system. Recently there is a focus on research in the therapeutic use of antigen feeding for immunization and/or oral tolerance induction. It is now well established that oral or intranasal immunization confers protection against a variety of viral and bacterial mucosal pathogens. On mucosal surfaces, secretory IgA antibodies elicit a whole series of biological responses such as agglutination of microorganisms, neutralization of bacterial enzymes, toxins, and viruses, and immune exclusion and inhibition of antigen or allergen absorption. Though conjectural, Spirulina may have a role in modulating these beneficial effects that result in the killing or inactivation of pathogens, antigens, and allergens, in addition to protection offered through the stimulation of cell-mediated immunity.

**ANTIOXIDANT EFFECTS**

A summary of studies related to the antioxidant effects of Spirulina is given in Table 2.

The antioxidant properties of Spirulina and its extracts have attracted the attention of researchers recently. In one of the earliest studies, Manoj et al. reported that the alcohol extract of Spirulina inhibited lipid peroxidation more significantly (65% inhibition) than the chemical antioxidants like α-tocopherol (35%), BHA (45%), and β-carotene (48%). The water extract of Spirulina was also shown to have more antioxidant effect (76%) than gallic acid (54%) and chlorogenic acid (56%). An interesting aspect of their findings is that the water extract had a significant antioxidant effect even after the removal of polyphenols.

In another study, by Zhi-gang et al., the antioxidant effects of two fractions of a hot water extract of Spirulina were studied using three systems that generate superoxide, lipid, and hydroxyl radicals. Both fractions showed significant capacity to scavenge hydroxyl radicals (the most highly reactive oxygen radical) but no effect on superoxide radicals. One fraction had significant activity in scavenging lipid radicals at low concentrations.

In a study by Miranda et al., the antioxidant activity of a methanolic extract of Spirulina was determined in vitro and in vivo. The in vitro antioxidant assay involved a brain homogenate incubated with and without the extract at 37°C. Peroxidation of rat brain homogenate was inhibited by almost 95% with 0.5 mg of the methanolic extract. The IC₅₀ of the extract in this system was found to be 180 µg. The in vivo antioxidant capacity was evaluated in plasma and liver of animals receiving a daily dose of 5 mg for 2 and 7 weeks. Plasma antioxidant activity in brain homogenate incubated at 47°C showed that the antioxidant capacity of plasma was 97% and 71% for the experimental group and 74% and 54% for the control group after 2 and 7 months. The antioxidant effect was attributed to beta carotene, tocopherol, and phenolic compounds working individually or in synergy.

In what appears to be the first report on antioxidant and anti-inflammatory properties of c-phycocyanin, Romay et al. showed that phycocyanin was able to scavenge hydroxyl (IC₅₀ = 0.91 mg/ml) and alkoxyl (IC₅₀ = 76 µg/ml) radicals with activity equal to 0.125 mg/ml of dimethyl sulfoxide (DMSO) and 0.038 µg/ml of trolox, specific scavengers of those radicals respectively. Phycocyanin also inhibited liver microsomal lipid peroxidation (IC₅₀ = 12 mg/ml). It is interesting to note that the oxygen-scavenging activity of c-phycocyanin was only 3 times lower than that of superoxide dismutase (SOD). The addition of SOD to the phycocyanin did not alter the antioxidant activity of the phycocyanin, suggesting a different mechanism of action. Further studies by the same group revealed that the anti-inflammatory activity of phycocyanin in some animal models of inflammation. Phycocyanin reduced significantly and in a dose-dependent manner the ear edema induced by arachidonic acid and tissue plasminogen activator in mice, as well as carageenan-induced rat paw edema. Phycocyanin also showed anti-inflammatory activity in a sub-chronic cotton pellet granuloma test where sterile cotton pellets were implanted in the axillae of rats. Oral administration of phycocyanin resulted in significant anti-inflammatory activity in all models tested. The anti-inflammatory activity observed was attributed to antioxidant and oxygen scavenging activity of phycocyanin and perhaps also due to its inhibitory effect on arachidonic acid metabolism. When compared with indomethacin, a standard anti-inflammatory drug, phycocyanin showed a weaker activity (50-300 mg/kg, p.o.) compared to 3-10 mg/kg, p.o., for the former. However, the LD₅₀ of indomethacin was 12 mg/kg in rats and 50 mg/kg in mice, p.o., and induces many side effects in patients under treatment. The LD₅₀ of phycocyanin in rats and mice was greater than 3g/kg, p.o. In fact, no mortality was observed even at 3 g/kg, p.o.

Vadiraja et al. studied the effect of c-phycocyanin from Spirulina platensis on carbon tetrachloride and R-(+)
pulegone-induced hepatotoxicity in rats. In this study a single dose (200 mg/kg) of phycocyanin was administered intraperitoneally to rats one or three hours prior to R-(+)-pulegone (250 mg/kg) or carbon tetrachloride (0.6 ml/kg) challenge. Phycocyanin significantly reduced the hepatotoxicity caused by these chemicals. Both chemicals are believed to cause hepatotoxicity due to the formation of free radicals. The hepatoprotective effect of phycocyanin was therefore attributed to the inhibition of reactions involved in the formation of reactive metabolites and possibly due to its radical scavenging activity. Duran et al. also found a similar hepatoprotective effect in experiments where rats were fed an oil extract of Spirulina or its defatted fraction. Recently, Bhat and Madayastha reported that c-phycocyanin from Spirulina effectively inhibited CCl₄-induced lipid peroxidation in rat liver in vivo. The inhibition by both native and reduced phycocyanin was
Table 2. Summary of studies on antioxidant effects of *Spirulina* or extract

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Summary of Studies</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>In vitro</em></td>
<td>The alcohol extract of <em>Spirulina</em> inhibited lipid peroxidation more significantly than the chemical antioxidants like α-tocopherol, BHA and β-carotene. Water extract showed more antioxidant activity than gallic acid and chlorogenic acid; antioxidant activity remained high even after removal of polyphenols.</td>
<td>33</td>
</tr>
<tr>
<td><em>In vitro</em></td>
<td>Two fractions of a hot water extract showed significant capacity of scavenging hydroxyl radicals (the most highly reactive oxygen radical); one of the fractions had significant activity in scavenging lipid radicals at low concentrations.</td>
<td>34</td>
</tr>
<tr>
<td><em>In vitro</em></td>
<td>Peroxidation of rat brain homogenate was inhibited by almost 95% with 0.5 mg of the methanolic extract. The IC50 of the extract in this system was found to be 180 μg.</td>
<td>35</td>
</tr>
<tr>
<td>Rat</td>
<td>Plasma antioxidant activity in brain homogenate incubated at 47°C showed that the antioxidant capacity of plasma was 97% and 71% for the experimental (<em>Spirulina</em> extract) group and 74% and 54% for the control group after 2 months and 7 months, respectively.</td>
<td>35</td>
</tr>
<tr>
<td><em>In vitro</em></td>
<td>Phycocyanin was able to scavenge hydroxyl (IC50 = 0.91 mg/ml) and alkoxyl (IC50 = 76 μg/ml) radicals The activity was equal to 0.125 mg/ml of dimethyl sulfoxide (DMSO) and 0.038 μg/ml of trolox Phycocyanin also inhibited liver microsomal lipid peroxidation (IC50 = 12 mg/ml).</td>
<td>36</td>
</tr>
<tr>
<td>Mice, Rats</td>
<td>Oral administration of phycocyanin reduced significantly and in a dose-dependent manner the ear oedema induced by Arachidonic Acid (AA) and tissue plasminogen activator (TPA) in mice, as well as carageenan-induced rat paw oedema.</td>
<td>37</td>
</tr>
<tr>
<td>Rats</td>
<td>Phycocyanin also showed anti-inflammatory activity in a sub-chronic cotton pellet granuloma test where sterile cotton pellets were implanted in the axillae of rats. When compared with indomethacin, a standard anti-inflammatory drug, phycocyanin shows a weaker activity (50-300 mg/kg, p.o.) compared to 3-10 mg/kg, p.o for the former. However the LD50 of indomethacin was 12 mg/kg in rats and 50 mg/kg in mice, p.o. The LD50 of phycocyanin in rats and mice was greater than 3g/kg, p.o.</td>
<td>37</td>
</tr>
<tr>
<td>Rats</td>
<td>Carbon tetrachloride (0.6 ml/kg) and R-(-)-pulegone (250 mg/kg)-induced hepatotoxicity in rats was reduced significantly when phycocyanin was administered intraperitoneally to rats one or three hours prior to the challenge.</td>
<td>38</td>
</tr>
<tr>
<td>Rats</td>
<td>A similar hepatoprotective effect as above was seen in actual feeding experiment in rats with an oil extract of <em>Spirulina</em> or its defatted fraction.</td>
<td>39</td>
</tr>
</tbody>
</table>
Table 2. Summary of studies on antioxidant effects of *Spirulina* or extract (continued)

| Rats | Oral administration of c-phycocyanin (100 mg/kg) in rats prevented kainic-acid-induced behavioral and glial reactivity in the rat hippocampus, crossing the hemato-encephalic barrier. The study also shows that phycocyanin reduces experimental status epilepticus. Authors postulate potential use of phycocyanin in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's, diseases induced by oxidative-stress-induced neuronal injury. | 40, 41 |
| In vitro | Phycocyanin inhibited 2,2'-azobis(2-methylpropanene)dihydroxochrome (AAPH)-induced human erythrocyte haemolysis in the same way as trolox and ascorbic acid, two well known antioxidants. Based on IC50 values phycocyanin was found to be sixteen times more efficient as an antioxidant than trolox and about 20 times more efficient than ascorbic acid. | 42 |
| In vitro | The antioxidant activity of phycocyanobilin (a component of phycocyanin) was greater than that of alpha tocopherol, zeaxanthin and caffeic acid on a molar basis. | 43 |
| In vitro | Phycocyanin from spray-dried *Spirulina* had a similar antioxidant activity as phycocyanin from fresh *Spirulina*. | 43 |
| Rats | C-phycocyanin from *Spirulina* effectively inhibited CCl4-induced lipid peroxidation in rat liver in vivo. Phycocyanin showed a potent peroxyl radical scavenger capacity with a rate constant-ratio of 1.54 compared to 3.5 for uric acid (a known peroxyl radical scavenger). | 40 |
| In vitro | Isolated enzyme assays and whole blood assays show that C-phycocyanin from *Spirulina platensis* is a selective inhibitor of cyclooxygenase-2 (COX-2) with a very low IC50 COX-2/IC50 COX-1 ratio (0.04). | 44 |
| In vitro | IC50 value obtained for COX-2 inhibition by phycocyanin was much lower (180 nM) as compared to those for celecoxib (255 nM) and rofecoxib (401 nM), the well-known selective COX-2 inhibitors. | 44 |
| In vitro | Potential role in hepatoprotection, anti-inflammatory and anti-arthritic action postulated. | 44 |
concentration-dependent with an IC$_{50}$ of 11.35 and 12.7 µM, respectively. Their studies have shown unequivocally that phycocyanin is a potent peroxyl radical scavenger with a rate-constant ratio of 1.54 compared to 3.5 for uric acid (a known peroxyl radical scavenger).

A recent interesting and elaborate study shows that oral administration of c-phycocyanin (100 mg/kg) in rats prevents kainic-acid-induced behavioral and glial reactivity in the rat hippocampus suggesting a corresponding protective effect on neurons. The study showed that phycocyanin reduced experimental status epilepticus, suggesting possible therapeutic intervention in the treatment of some forms of epilepsy. According to the authors, kainic acid (KA) triggered excitotoxicities resulted in the production of reactive oxygen species. It is therefore postulated that the protective effect of phycocyanin in neuronal damage may be due to its free-radical scavenging and antioxidant properties.

An interesting aspect of this study is the finding that oral administration of phycocyanin exerts its effect in the hippocampus, crossing the hematoencephalic barrier. According to the authors, these findings and the virtual lack of toxicity of phycocyanin suggest that this phytochemical could be used in the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, diseases brought on by oxidative stress-induced neuronal injury.

Moreover, Romay’s group has recently reported that phycocyanin inhibited 2,2‘-azobis(2-mimidoprapane)dihydroxychloride (AAPH)-induced erythrocyte haemolysis in the same way as trolox and ascorbic acid, well-known antioxidants. Based on IC$_{50}$ values (concentration of the additive that gave the 50% inhibition of peroxidative damage), phycocyanin was found to be 16 times more efficient as an antioxidant than trolox and about 20 times more efficient than ascorbic acid. These findings were supported by a more recent study that showed that the antioxidant activity of phycocyanobilin (a component of phycocyanin) was greater than that of alpha tocopherol on a molar basis. The antioxidant effect of phycocyanobilin was evaluated against oxidation of methyl linolate in a hydrophobic system or with phosphatidylcholine liposomes. The study also showed that phycocyanin from spray-dried Spirulina had a similar antioxidant activity as phycocyanin from fresh Spirulina. The results suggest that the antioxidant activity of phycocyanin is attributable to phycocyanobilin, a prohetic group in phycocyanin since the apoprotein component may be denatured upon drying. The fact that the dried phycocyanin showed the same level of activity as the intact protein makes the preparation and utilization of phycocyanin commercially feasible.

According to Reddy et al., c-phycocyanin from Spirulina platensis is a selective inhibitor of cyclooxygenase 2 (COX-2) with a very low IC$_{50}$ COX-2/IC$_{50}$ COX-1 ratio (0.04). Interestingly, their study showed that the IC$_{50}$ value obtained for COX-2 inhibition by phycocyanin was much lower (180 nM) as compared to those for celecoxib (255 nM) and rofecoxib (401 nM), the well-known selective COX-2 inhibitors. The apoprotein component of phycocyanin was responsible for the inhibition of COX-2 since reduced phycocyanin and phycocyanobilin were found to be ineffective. The authors suggest that the hepatoprotective, anti-inflammatory, and anti-arthritic properties of phycocyanin reported in the literature might be due, in part, to its selective COX-2 inhibitory property, though they did not exclude a similar effect of phycocyanin through its ability to efficiently scavenge free radicals and inhibit lipid peroxidation.

**IMPLICATIONS OF THE STUDIES**

The relationship between antioxidant intake and incidence of chronic diseases such as cancer, cardiovascular disease, cataracts, and premature aging is now well established through many epidemiological, intervention, and clinical studies. This strong association between diet and cancer led the National Cancer Institute to initiate the 5-A-Day Program in 1991, recommending 5 servings of fruits and vegetables daily. The United States Department of Agriculture recommends 5-9. Surveys show that only 23% of adult Americans consume the recommended level, and the median level was about 3 servings a day. People whose lifestyle choices preclude eating properly may want to improve their diets by adding nutritional supplements rich in antioxidants.

While the connection between the consumption of fruits and vegetables and the incidence of disease cannot be attributed to the antioxidant components alone, many studies suggest that antioxidants play the major role. Fruit and vegetable antioxidants are derived from the carotenoid pigments. Spirulina provides an adequate amount of a spectrum of carotenoid pigments, especially beta carotene (associated with cancer prevention) and zeaxanthin (associated with prevention of age-related macular degeneration (AMD). In this respect Spirulina is a “microvegetable” that can provide some of the antioxidants needed. Many studies have also revealed that antioxidants like the carotenoids in fruits, vegetables, and Spirulina have a synergistic effect. Thus whole-food supplements are expected to provide more antioxidant protection compared to individual components. Spirulina also contains phycocyanin and polysaccharides, both known to have antioxidant properties. In addition, antioxidants that have a direct effect on reactive oxygen species, Spirulina contains an important enzyme, superoxide dismutase, that acts indirectly by slowing down the rate of oxygen radical generating reactions.

The results of the studies summarized above point to the potential use of Spirulina together with other conventional approaches in a nutritional supplementation strategy.
geared toward the prevention and mitigation of health problems like cancer, heart disease, and premature aging that are associated with free radical damage. In the context of using Spirulina as an antioxidant, it is worth noting that it contains about 7% phycocyanin (dry weight basis) and a relatively high content of superoxide dismutase (1,700 units/g) in addition to a high content of mixed carotenoids. A significant aspect of these studies is that orally-administered phycocyanin is bioavailable and can even pass the blood-brain barrier. The role of phycocyanin in COX-2 inhibition may also result in the potential application of Spirulina in the management of inflammatory conditions and toxicity due to chemicals and drugs.

**ANTICANCER EFFECTS**

The antioxidative and immune modulation effect of Spirulina and its extracts discussed above are to a certain extent associated with Spirulina’s cancer prevention potential. In this summary we report only those studies targeted directly at cancer research. Table 3 summarizes the studies on anti-cancer effects of Spirulina.

The only human study on the effect of Spirulina on chemoprevention of cancer is that by Mathew et al., who studied the effect of Spirulina on oral leukoplakia (a precancerous lesion) in pan tobacco chewers in Kerala, India. In a study involving 44 subjects in the intervention group and 43 in the placebo group, they found that supplementation with Spirulina at 1 g/day for 1 year resulted in complete regression of lesions in 45% of the intervention group and 7% in the control group. The effect was more pronounced in homogeneous lesions. Since supplementation with Spirulina did not result in increased serum concentrations of retinal beta carotene, the authors concluded that other constituents in Spirulina may be responsible for the regression of lesions observed. The results of this study are significant because, even in developed countries, tobacco use is the cause of 30% of the incidence of cancer, with the greatest influence on lung and oral cancer. As recommended by the authors, it is worth investigating this potentially useful aspect of Spirulina in more rigorous human trials. If Spirulina proves to have such effect, it can easily be incorporated in the daily diet as a therapeutic agent.

The human oral cancer study corroborates the results found in earlier studies on the effect of Spirulina and Dunaliella extract on experimental cancer in hamster buccal pouches. Schwartz and Shklar studied the effect of administration of 250 µg of the extract in 0.1 ml of MEM (minimum essential medium) directly to DMBA (7,12-dimethylbenz(a)-anthracene)-induced squamous cell carcinoma of hamster buccal pouches. Other treatments included injection of beta carotene, canthaxanthin, 13-cis-retinoic acid and sham-injected controls. All treatments involved 250 µg in 0.1 ml MEM twice weekly for 4 weeks. After four weeks of treatment, total tumor regression was found in 30% of the animals treated with extract, 20% of the beta carotene-treated animals, and 15% of canthaxanthin-treated animals. Partial tumor regression was found in the remaining 70% of the extract-treated animals. An interesting observation of this study is that the algae extract appears to be more effective than beta carotene alone, suggesting a synergistic effect between the various components of the algae. In another study Schwartz et al. have shown that algae-derived phycocyanin had a cytostatic and cytotoxic activity against squamous cell carcinoma (human or hamster). Phycocyanin may have played a synergistic effect here as well as in the human study reported above. In subsequent studies, Schwartz et al. were able to demonstrate that an extract of Spirulina and Dunaliella administered orally (140 µg every 3 days for 28 days) prevented tumor development in hamster buccal pouches. Carcinomas that were beginning to develop were destroyed in what appeared to be an immune response. This was surmised from the dense lymphocytic-monocytic infiltrate observed. The monocytes were found to be cytotoxic to tumor target cells in vitro and the lymphocytes were found to be T-cells. Thus the algae extract was believed to prevent cancer development by stimulating an immune response to selectively destroy small initial foci of developing malignant cells. It is worth noting that the algae extract was not cytotoxic to normal cells in all experiments performed.

In a murine model, Lisheng et al. found that a polysaccharide extract of Spirulina inhibited the proliferation of ascitic hepatoma cells of mice injected at a dose of 200 mg/kg. In this study 36 healthy female mice were injected with 5x10⁶ of ascitic hepatoma cells, and the controls were injected with distilled water. On the second day after injection of the hepatoma cells, 200 mg/kg/day of polysaccharide from Spirulina platensis was injected for 6 days. Another group (prevention group) was injected with the polysaccharide for 5 days before the injection of the hepatoma cells. Quantification of the ascites was done 6 days after injection of the hepatoma cells. Compared to the control group, those treated with the extract after the transplantation of the tumor showed a 54% reduction in tumor progression, while those where the extract was administered five days before tumor transplantation showed a 91% decrease in tumor progression. According to Chen et al., the number of aberrant crypts formed in the colon of rats by a single or multiple injection of 1,2-dimethyl hydrazine (DMH) was reduced significantly (p<0.01) in rats fed Spirulina particularly during weeks 13 and 16 after injection.

Recently, Mishima et al. have elegantly demonstrated inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel polysaccharide isolated from Spirulina platensis. Seven intermittent i.v. injections of 100 µg of Ca-SP in mice caused a marked decrease of lung tumor colonization of B-16-BL6 cells in a spontaneous lung metastasis.
Table 3. Summary of studies on anticancer and antiviral effects of *Spirulina* or its extracts

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Summary of Studies</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>In a study involving 44 subjects in the intervention group and 43 in the placebo group supplementation with <em>Spirulina</em> at 1 g/day for 1 year resulted in complete regression of oral leukoplakia in pan tobacco chewers in India. Complete regression was observed in 45% of the intervention group compared to only 7% in the control group.</td>
<td>46</td>
</tr>
<tr>
<td>Hamsters</td>
<td>Administration of 250 μg of a <em>Spirulina/Dunaliella</em> extract (in 0.1 ml of minimum essential medium, MEM) directly to 7,12 dimethylbenz(a)-anthracene (DMBA)-induced squamous cell carcinoma of hamster buccal pouches resulted in total tumor regression in 30% of the animals treated with extract 20% of the beta-carotene-treated animals and 15% of canthaxanthin-treated animals showed complete regression. Partial tumor regression was found in the remaining 70% of the extract-treated animals.</td>
<td>48</td>
</tr>
<tr>
<td>Human and Hamsters</td>
<td>Algae-derived phycocyanin had a cytostatic and cytotoxic activity against squamous cell carcinoma (human or hamster).</td>
<td>50</td>
</tr>
<tr>
<td>Hamsters</td>
<td>An extract of <em>Spirulina</em> and <em>Dunaliella</em> administered orally (140 μg every 3 days for 28 days) prevented tumor development in hamster buccal pouches. The dense lymphocytic-monocytic infiltrate observed suggested that the anticancer effect could be due to an immune response. The algae extract was not cytotoxic to normal cells in all experiments performed.</td>
<td>49</td>
</tr>
<tr>
<td>Mice</td>
<td>A polysaccharide extract of <em>Sphrulina</em> inhibited the proliferation of ascitic hepatoma cells of mice injected at a dose of 200 mg/kg. The group treated with the extract after the transplantation of the tumor showed a 54% reduction in tumor progression. The group where the extract was administered five days before tumor transplantation showed a 91% decrease in tumor progression.</td>
<td>51</td>
</tr>
<tr>
<td>Rats</td>
<td>The number of aberrant crypts formed in the colon of rats by a single or multiple injection of 1,2-dimethyl hydrazine (DMH) was reduced significantly (p&lt;0.01) in rats fed <em>Spirulina</em>.</td>
<td>52</td>
</tr>
<tr>
<td>Mice</td>
<td>Seven intermittent i.v. injections of 100 μg of Ca-SP in mice caused a marked decrease of lung tumor colonization of B16-BL6 cells in a spontaneous lung metastasis model.</td>
<td>53</td>
</tr>
</tbody>
</table>
Table 3. Summary of studies on anticancer and antiviral effects of *Spirulina* or its extracts (continued)

<table>
<thead>
<tr>
<th>Mice</th>
<th>C-phycocyanin from <em>Spirulina</em> inhibited the growth of K562 leukemia cells in a dose-dependent manner with statistically significant inhibition observed at 80 and 160 mg l⁻¹. The IC₅₀ value of C-PC was found to be 72.5 mg l⁻¹ in XTT dye reduction assay.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>In vitro</em> Water extract of <em>Spirulina platensis</em> inhibited the replication of <em>Herpes simplex</em> virus type (HSV-1) in HeLa cells within the concentration range of 0.08-50 mg/ml. Extract did not have virucidal effect but interfered with the adsorption and penetration into hose cells. The ID₅₀ for cytopathy of the extract to HeLa cells was 26.3 mg/ml, while the ED₅₀ for antiviral activity was found to be 0.173 mg/ml, giving an <em>in vitro</em> therapeutic index of 152. In an experimental study of HSV-1 corneal infection of hamsters, food containing the extract effectively prolonged the survival time of infected hamsters at doses of 100 and 500 mg/kg.</td>
</tr>
<tr>
<td></td>
<td><em>In vitro</em> Calcium spirulan (Ca-SP) from <em>Spirulina platensis</em> found to inhibit the replication of several enveloped viruses including <em>Herpes simplex</em> virus type I (HSV-1), human cytomegalovirus (HCMV), measles virus, mumps virus, influenza A virus, and HIV-1 virus.</td>
</tr>
<tr>
<td></td>
<td><em>In vitro</em> The anti-HIV-1 activity of Ca-SP was found to be comparable to dextran sulfate, a known potent anti-HIV-1 agent, and its anti-HSV-1 activity was four to five-fold higher than that of dextran sulfate. The anti-HIV-1 activity of Ca-SP or DS was five and four times higher in cultures treated with Ca-SP or DS during infection when compared with that in cultures treated after infection. Ca-SP was considered superior to DS in possible therapeutic application.</td>
</tr>
<tr>
<td></td>
<td><em>In vitro</em> An aqueous extract <em>Spirulina (Arthrospira) platensis</em> inhibited HIV-1 replication in human T-cell lines, peripheral blood mononuclear cells (PBMC), and Langerhans cells. The extract inactivated HIV-1 infectivity directly when pre-incubated with virus before addition to human T-cell lines.</td>
</tr>
</tbody>
</table>
model. Their studies of the invasion of B16-BL6 melanoma, colon 26 M3.1 carcinoma, and HT-1080 fibrosarcoma cells through reconstituted basement membrane (Matrigel) shed light on the mechanism of the inhibition of the invasion. The authors suggest that Ca-SP could reduce lung metastasis of B16 - BL6 melanoma cells by inhibiting the tumor invasion of basement membrane, probably through heparanase activity and through the prevention of the adhesion and migration of tumor cells to laminin substrate. Their results showed that Ca-SP strongly inhibited the degradation of heparan sulfate by purified heparanase. According to these workers, this remarkable anti-heparanase activity might provide a promising basis for improved therapeutic approaches to tumor invasion and metastasis.53

In a very recent study by Gustafson et al. (2000), c-phycocyanin (C-PC) from *Spirulina platensis* inhibited the growth of human leukemia K562 cells. The effect of phycocyanin was at first studied following the growth of the K562 cells in semi-solid agar culture at concentrations of 20, 40, 80, and 160 mg·l-1. The results showed that phycocyanin inhibited the growth of the K562 leukemia cells in a dose-dependent manner with statistically significant inhibition observed at 80 and 160 mg·l-1. The effect of phycocyanin was further studied using cell viability measurement using XTT dye reduction assay. Phycocyanin was again found to inhibit cell viability in a dose-and time-dependent manner. The IC50 value of C-PC was found to be 72.5 mg·l-1. Furthermore, flow cytometric assay based on DNA content analysis revealed that accumulation of K562 cells occurred in the G-1 phase when cells were incubated in C-PC for 6 days. There were higher percentages of cells in the G-1 phase at phycocyanin concentrations of 40 and 80 mg·l-1. DNA fragment analysis did not show the ladder formation typically observed in apoptosis, indicating that a different mechanism may be at play in the inhibition process.54

According to a Japanese patent, oral administration of phycocyanin extracted from *Spirulina* was found to increase the survival rate of mice that had been injected with liver tumor cells. The lymphocyte activity of the treatment group was significantly higher than that of the control group, suggesting some sort of stimulation of the immune system.

Another study of interest is that by Qishen et al. who reported enhancement of endonuclease activity and repair DNA synthesis by polysaccharides of *Spirulina platensis*. The effect of the extract was studied by means of endonuclease assay and radioautography. The results showed that the presence of the extract significantly enhanced both the repair activity of radiation-damaged DNA excision and the unscheduled DNA synthesis. The same group also found that an extract of *Spirulina platensis* caused a significant reduction of micronucleus frequencies induced by gamma-radiation in mouse bone marrow cells.

**IMPLICATIONS OF THE STUDIES**

Doll and Peto did the landmark study establishing that 35% of all human cancer deaths appear to be associated with diet and nutrition. Since then numerous experimental, epidemiological, and clinical studies have proved this connection. These studies have demonstrated conclusively that numerous nutrient and non-nutrient constituents in foods in our diet have the potential to confer chemopreventive properties or enhance conventional therapy. For example, there is evidence that vegetables and fruits, rich sources of antioxidants like vitamin C, E, and beta carotene, might protect against different forms of cancer. There is also a recent body of evidence to suggest that physiological aging of the immune system may affect cell-mediated immunity that in turn results in cancer development, autoimmune disease, and susceptibility to infection.

Radiation, chemotherapy, and surgery therapies cause side effects often worse than the cancer itself. Preventive and mitigation methods utilizing natural products directly or as adjuvant to conventional cancer treatment are therefore the focus of recent research. The studies summarized above suggest such a role for *Spirulina*. *Spirulina* may offer some degree of protection against certain forms of cancer through its effect on the immune system, through a direct effect in the repair of DNA, and antioxidant protection from reactive oxygen species generated during normal or abnormal metabolism and from toxic substances in the environment. Further research along these lines is recommended to validate these assumptions.

**ANTI-VIRAL EFFECTS**

A summary of the studies on the anti-viral effects of *Spirulina* is given in Table 3.

Interest in the study of antiviral effects of *Spirulina* was triggered by a report from researchers at the National Cancer Institute about the discovery of potent antiviral compounds from extracts of blue-green algae. Gustafson et al. found that sulfonic-acid-containing glycolipids isolated from *Lyngbya lagerheimii* and *Phormidium tenue* were active against HIV-1 in cultured human lymphoblastoid CEM, MT-2, LDV-7, and C3-44 cell lines. At the time, these sulfolipids were given high priority by the NCI for further preclinical investigations and for evaluation of feasibility as candidates for clinical testing. In subsequent studies this group screened about 600 strains of cultured cyanobacteria representing some 300 species. Approximately 10% of the cultures produced substances that caused significant reduction in cytopathic effects normally associated with viral infection.

According to Hayashi et al., the water extract of *Spirulina platensis* inhibited the replication *in vitro* of Herpes simplex virus type (HSV-1) in HeLa cells within the concentration range of 0.08-50 mg/ml. The extract did not have virucidal effect but interfered with the adsorption and
that inhibits the replication of novel sulfated-polysaccharide, calcium spirulan (Ca-SP), which has become pandemic. Conventional anti-HIV drugs are most prominent viral disease, HIV/AIDS, has now claimed the emergence of new antibiotic-resistant bacteria and viruses. The therapeutic index of the extract to HeLa cells was 26.3 mg/ml, while the ED50 for antiviral activity was found to be 0.173 mg/ml, giving an in vitro therapeutic index of 152. In an in vivo study involving experimental HSV-1 corneal infection of hamsters, they found that food containing the extract effectively prolonged the survival time of infected hamsters at doses of 100 and 500 mg/kg. From the data obtained in the in vivo study the authors postulated that Spirulina supplementation might prevent herpetic encephalitis.

Hayashi et al. isolated from Spirulina platensis a novel sulfated-polysaccharide, calcium spirulan (Ca-SP), that inhibits the replication in vitro of several enveloped viruses including Herpes simplex type I (HSV-1), human cytomegalovirus (HVMV), measles virus, mumps virus, influenza A virus, and HIV-1 virus. In a later study, Hayashi et al. found that the anti-HIV-1 activity of Ca-SP is comparable to that of dextran sulfate (DS; a known potent anti-HIV-1 agent), while its anti-HSV-1 activity was four- to five-fold higher than that of dextran sulfate. The anti-HIV-1 activity of Ca-SP or DS was five and four times higher in cultures treated with Ca-SP or DS during infection when compared with that in cultures treated with these substances after infection. Ca-SP was found to be superior to DS in possible therapeutic application because 1) enhancement of viral replication at low concentrations, a usual phenomenon in DS, was not observed with Ca-SP, 2) Ca-SP was found to have a much lower anticoagulant effect than DS, 3) Ca-SP was found to have a much longer half-life in the blood of mice compared to DS, and 4) Ca-SP was four to five times more effective in inhibiting HSV-1 compared to DS.

More recently, Ayehunie et al. reported that an aqueous extract of Spirulina (Arthrospira) platensis inhibited HIV-1 replication in human T-cell lines, peripheral blood mononuclear cells (PBMC), and Langerhans cells. Depending on the cell type used, therapeutic indices (EC50/IC50) ranged between 200 and 6,000. The extract inactivated HIV-1 infectivity directly when pre-incubated with virus before addition to human T-cell lines. These authors found antiviral activity both in the polysaccharide fraction as well as in a fraction depleted of polysaccharides and tannins. The authors believe that the aqueous extract of S platensis might be of potential clinical interest.

**IMPLICATIONS OF THE STUDIES**

Abuse and misuse of antibiotics has resulted in the emergence of new antibiotic-resistant bacteria and viruses. The most prominent viral disease, HIV/AIDS, has now claimed the lives of millions of people. In Africa and Asia, HIV/AIDS has become pandemic. Conventional anti-HIV drugs are beyond the reach of ordinary people. Vaccines are still a long way to come. It is apparent that alternative sources be sought. Therapeutic use of herbs and algae products with known bacterial and virucidal properties may offer alternative approaches. Whole-plant products and crude extracts often have ingredients that may work synergistically to effect viral or bacterial killing or inactivation. Resistance to these varied substances may not be as easy as to one single antibiotic. It is also known, at least for some natural products, that they exert their protective effect through stimulation or modulation of the immune system. Therefore instead of trying to find the magic chemical bullet to kill viruses or bacteria, the body’s immune system is activated to protect against infection. Such an approach will also be useful even after infection sets in. For example, HIV/AIDS sufferers are usually affected by opportunistic infection once the virus debilitates the immune system. Enhancement of the immune system through therapeutic intervention with natural products may offer protection against such infection.

As summarized in the studies above, the antiviral activity of the aqueous extract of Spirulina has been demonstrated in various in vitro and animal models. The active component of the extract appears to be Ca-SP. This compound could be a good candidate for therapeutic intervention against HIV-1 and other viruses because of its low anticoagulant activity, long half-life in the blood, and dose-dependent bioactivity without stimulation of viral replication at low concentration. Moreover Ca-SP has been shown to inhibit a host of other viruses that cause opportunistic infection by HIV-1 like cytomegalovirus and Herpes simplex virus. As far as therapeutic use is concerned, the aqueous crude extract has been shown to have similar effects. The crude extract has a potential to be used as a dietary supplement to offer an adjuvant effect to conventional treatment of viral infections. Since the polysaccharide extract is known to boost the immune system, the antiviral effect (inhibition of replication or attachment) may be augmented by the enhancement of the overall immune response of the body. This potential needs to be investigated further in more animal models and humans and under different modes of administration before conclusions are drawn about the effectiveness of such use.

**EFFECTS ON HYPERLIPIDEMIA**

A summary of studies on the cholesterol-regulatory properties of Spirulina is given in Table 4. One of the earlier studies on the reduction of serum cholesterol by Spirulina was that done on rats by Devi and Venkataraman. Since then several workers have confirmed this in studies involving animals and humans.

In an elaborate study involving feeding rats with high cholesterol diets with and without Spirulina supplementation, Kato et al. found that the elevation of total choles-
Table 4. Summary of studies on cholesterol reduction and related effects

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Summary of Studies</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mice</td>
<td>The elevation of total cholesterol, LDL+VLD cholesterol and phospholipids in the serum was reduced significantly when the high experimental cholesterol diet was supplemented with 16% <em>Spirulina</em>. The reduction in HDL cholesterol caused by the high cholesterol diet was also reduced in the mice fed the high cholesterol diet in the presence of <em>Spirulina</em>. Adiposehepatosis induced by a high fat and high cholesterol diet was also reduced rapidly when the mice were shifted from the high fat high cholesterol diet to a basal medium supplemented with <em>Spirulina</em>.</td>
<td></td>
</tr>
<tr>
<td>Rats</td>
<td>Liver levels of triglycerides and phospholipids in rats fed a diet supplemented with 5% <em>Spirulina</em> were significantly lower than rats fed either 60% glucose or 60% fructose.</td>
<td>74</td>
</tr>
<tr>
<td>Rats</td>
<td>Levels of triglycerols and cholesterol were found to be significantly lower in rats on a diet supplemented with <em>Spirulina</em> compared to those on control diets. Prior to the measurement, fatty liver was induced by a single intraperitoneal injection (1 ml/kg) of carbon tetrachloride to both the control and experimental rats.</td>
<td>75</td>
</tr>
<tr>
<td>Rats</td>
<td>Feeding <em>Spirulina</em> at 5%, 10%, and 15% of the diet resulted in a significant inhibition of total and HDL-cholesterol (p&lt; 0.01), triglyceride (p&lt; 0.05) and phospholipid (p&lt; 0.01) in fructose-induced hypolipidemic rats. The <em>Spirulina</em> diet group showed a statistically significant (p&lt;0.01) increase in the activity of LPL than the high fructose diet group suggesting role of LPL in lowering triglycerides.</td>
<td>76, 77</td>
</tr>
<tr>
<td>Rats</td>
<td>Rats fed 20% water-soluble fraction of <em>Spirulina</em> were found to have a high HDL to LDL ratio and and low fasting serum glucose levels compared to rats fed a water-soluble fraction or casein.</td>
<td>78</td>
</tr>
<tr>
<td>Mice</td>
<td>Compared to the control group the <em>Spirulina</em>-supplemented mice showed significantly lower levels of total HDL and LDL cholesterol (31%, 20%, and 54% reduction, respectively) after 14 days of feeding. Further reduction in cholesterol levels was observed after 35 days of feeding. The HDL to LDL cholesterol ratio was found to be significantly higher (2 to 2.4-fold increase) in mice fed <em>Spirulina</em>. In mice fed <em>Spirulina</em> for 35 days, plasma levels of triglycerides decreased by 44% compared to the control group.</td>
<td>80</td>
</tr>
</tbody>
</table>
terol, LDL+VDL cholesterol, and phospholipids in the serum was reduced significantly when the experimental high cholesterol diet was supplemented with 16% *Spirulina*. The fall in HDL cholesterol caused by the high cholesterol diet was also reduced in mice fed the high cholesterol diet in the presence of *Spirulina*. Adipohepatosis induced by a high fat and high cholesterol diet was also reduced rapidly when the mice were shifted from the high fat, high cholesterol diet to a basal medium supplemented with *Spirulina*. Their findings were supported by more recent studies. De Rivera *et al.* measured liver levels of triglycerides and phospholipids in rats fed a diet supplemented with 5% *Spirulina*, and either 60% glucose or 60% fructose. The control animals were fed either 60% glucose or 60% fructose. Rats fed the *Spirulina* diet had lower levels of liver triglycerides and phospholipids compared to control groups. Torres-Duran *et al.* studied the effect of *Spirulina* on liver and serum lipid levels of rats where fatty liver was induced by a single intraperitoneal injection (1 ml/kg) of carbon tetrachloride. Liver lipid concentrations did not change in rats fed the purified diet with or without *Spirulina*. However, after carbon tetrachloride treatment, liver triglycerols and cholesterol were significantly lower in rats fed the *Spirulina*.

In a study involving rats, Iwata *et al.* found that feeding *Spirulina* at 5%, 10%, and 15% of the diet resulted in a significant inhibition of total and HDL-cholesterol (p<0.01), triglyceride (p<0.05) and phospholipid (p<0.01) in fructose-induced hypolipidemic rats. However, no difference in liver lipids was found between the high fructose diet and *Spirulina* diet groups. In a subsequent study Iwata *et al.* attempted to elucidate the mechanism of the hypotriglyceridemic effect of *Spirulina*, by studying the activities of two kinds of lipases, lipoprotein lipase (LPL) and hepatic triglyceride lipase (H-TGL). The *Spirulina* diet group showed a statistically significant (p<0.01) increase in the activity of LPL than the high fructose diet group. There was no significant difference in the activity of H-TGL in the two groups. Since LPL is a key lipolytic enzyme in the metabolism of TG-rich lipoproteins, it was postulated that the hypotriglyceridemic effect of *Spirulina* might be through its effect on the metabolism of lipoproteins.

Rats fed a 20% water-soluble fraction of *Spirulina* were also found to have a high HDL to LDL ratio and a low fasting serum glucose level compared with rats fed a water insoluble fraction or casein. A significant increase in HDL cholesterol was also found in another study. Additional evidence for cholesterol-regulating effect comes from Fong *et al.* who studied the effect of *Spirulina* on plasma cholesterol and triglyceride levels in mice. Compared to the control group the *Spirulina*-supplemented mice showed significantly lower levels of total, HDL and LDL cholesterol (31%, 20%, and 54% reduction, respectively) after 14 days of feeding. Further reduction was observed after 35 days of feeding. The HDL to LDL cholesterol ratio was found to be significantly higher (2- to 2.4-fold increase) in mice fed *Spirulina*. In mice fed *Spirulina* for 35 days, plasma levels of triglycerides decreased by 44% compared to the control group.
However, there was no difference in triglyceride levels in the *Spirulina* and control groups after 14 days of feeding.80

To date, there are three published reports of cholesterol-reduction effects of *Spirulina* in humans. In the first study by Nakaya et al.,81 30 male volunteers with mild hyperlipidemia and mild hypertension were divided into two groups. Group A subjects were given *Spirulina* at 4.2 g/dl and group B subjects were given the same amount of *Spirulina* for 4 weeks and were observed for the next 4 weeks without giving *Spirulina*. The results showed a statistically significant reduction of LDL-cholesterol (p< 0.05) in group A subjects after 8 weeks. The LDL-cholesterol also fell significantly in group B subjects after 4 weeks (p<0.05), but thereafter increased to its baseline value after the administration of *Spirulina* was discontinued. No significant difference was observed in the level of HDL cholesterol. On the other hand, the atherogenic index (a measure of fat deposition in arteries) declined significantly in group A subjects (p<0.01) after 4 weeks.81

Ramamoorthy and Premakumari82 studied 30 ischemic heart disease patients with blood cholesterol levels above 250 g/dl. Divided into three groups of 10, group A and B subjects were given 2 g and 4 g *Spirulina* per day, respectively, for 3 months, and group C served as control. The group with *Spirulina* supplementation had significantly lower blood cholesterol, triglycerides, LDL and VLDL cholesterol 1 and higher HDL cholesterol. Supplementation with 4 g per day *Spirulina* showed a higher effect than a 2 g dose in reducing serum total cholesterol and LDL.

In a human clinical study involving 15 diabetic patients, Mani et al.83 found a significant reduction in total lipids, free fatty acids, and triglyceride levels. A reduction in LDL/HDL ratio was also observed.

**IMPLICATIONS OF THE STUDIES**

Collectively the results of the animal and human studies summarized above provide support for the cholesterol-lowering activity of *Spirulina*.

A vast amount of experimental and epidemiological evidence shows the connection between diets high in fat and cholesterol and the incidence of cardiovascular disease. There is also an increased awareness among Americans that diets high in cholesterol present a risk of cardiovascular disease. Despite this, cardiovascular disease is the number one killer in the United States, claiming about one million lives a year and totaling 41% of all deaths. It is often said that a fast lifestyle makes it difficult for many Americans to make proper food choices. Supplementation with natural food supplements like *Spirulina* may contribute, in part at least, to an overall strategy to manage this serious health problem.

**OTHER EFFECTS**

This section sheds light on less extensively studied potential applications of *Spirulina*.

**Probiotic effects**

Tsuchihashi et al.84 found that an intake of *Spirulina* at 5% of the diet increased the population of *Lactobacillus* in the caecum of rats by 3 times over a control group of rats not fed *Spirulina*.84 Similar results were obtained by de Mule85 in *in vitro* studies with *Lactobacillus lactis* and *Candida albicans*.86 More recently Parada et al.86 have reported a stimulatory effect of extracellular products from algae on lactic acid bacteria including *Lactococcus lactis*, *Streptococcus thermophilus*, *Lactobacillus casei*, *Lactobacillus acidophilus*, and *Lactobacillus bulgaricus*.

In humans, *Lactobacillus* is believed to have three functions: to improve digestion and absorption of foods, to protect from infection, and to stimulate the immune system. In patients with an Acquired Immune Deficiency Syndrome (AIDS), nutrient malabsorption associated with opportunistic infections from microorganisms like *Candida albicans* can speed expression of disease symptoms. One recommended strategy for halting the progression of AIDS is based on nutrient supplementation as well as supplemental *Lactobacillus*.87 *Spirulina* might offer such a nutritional and therapeutic strategy.

**Effects against diabetes, obesity, and blood circulation**

According to Takai et al.,88 a water-soluble fraction of *Spirulina* was found effective in lowering the serum glucose level at fasting while the water-insoluble fraction suppressed glucose level at glucose loading.88 Similar results were found in other studies.78-79 In a human clinical study involving 15 diabetics, a significant decrease in the fasting blood sugar level of patients was observed after 21 days of 2 g/day *Spirulina* supplementation.83 In a double-blind-crossover study versus placebo, Becker et al.89 have found that a supplementary diet of 2.8 g of *Spirulina* 3 times d-1 over 4 weeks resulted in a statistically significant reduction of body weight in obese outpatients. *Spirulina* has also been found to suppress high blood pressure in rats.90 A vasodilating property of rat aortic rings by *Spirulina* possibly dependent upon a cyclooxygenase-dependent product of arachidonic acid and nitric oxide has been reported by Paredes-Carbajal et al.91

Cheng-Wu Z et al.92 did a preliminary study on the effect of polysaccharides and phycocyanin on peripheral blood and hematopoietic system of bone marrow in mice. Their studies showed that C-phycocyanin and polysaccharides from *Spirulina* had a high erythropoietin (EPO) activity.

**Effects against toxicities from heavy metals and other compounds**

According to Yamane et al.,93 rats with high mercury dosage showed rising blood urea nitrogen (BUN) and serum creatinine, both indicators of acute nephritis. The addition of 30% *Spirulina* in the diet resulted in a significant decrease in BUN and serum creatinine levels. Rats
given 3 pharmaceuticals, para-aminophenol (anodyne), gentamicin (antibiotic), and cis-dichlorodiamino-platinum (anti-cancer), showed similar kidney improvement on a Spirulina diet.\textsuperscript{93} In a follow-up study, Fukino et al.\textsuperscript{94} found similar effects of Spirulina on renal toxicity induced by inorganic mercury and cisplatin. In addition to BUN and serum creatinine, urinary excretion of alkaline phosphatase (ALP) and glutamic oxaloacetate transaminase (GOT) were measured as further indicators of renal function. The activities of both enzymes were significantly reduced in the group fed 30% Spirulina. The effective component was found in the water-soluble fraction of the Spirulina extract, within which the substances with a molecular weight of more than 100,000 were believed to be responsible. From this observation it was suggested that phycocyanin might be responsible in the suppression of renal toxicity.\textsuperscript{94} Hepatoprotection from toxic compounds has already been discussed above under antioxidant effects of Spirulina. Shastri et al.\textsuperscript{95} did studies on the protective role of dietary Spirulina on lead toxicity in Swiss albino mice. They observed a significant increase in the survival time in pre- and post-treated Spirulina compared with a control group without Spirulina. Lead-induced toxicities were reduced as suggested by the higher testes weight, animal weight, and tubular diameter in the Spirulina treated group.

Radiation protection effects

The radioprotective effect of a crude ethanol precipitate (CEP) of Spirulina platensis was studied using the micronucleus test in polychromatic erythrocytes (PCE) of mouse bone marrow. In this system the extract caused a significant reduction of micronucleus frequencies induced by γ-radiation. Gamma-radiation followed by treatment with CEP led to about the same radioprotective effect as CEP treatment followed by γ-radiation. From this the authors concluded that the protective compound probably acts as a DNA-stabilizing factor, and they ruled out the possibility of a radical scavenging mechanism.\textsuperscript{57} The ability of CEP to reduce the incidence of micronucleated mouse marrow cells is believed to reflect its antimutagenic and repair-stimulating capacities much as has been postulated by Schwartz et al.\textsuperscript{49}

Mazo et al.\textsuperscript{96} subjected rats to gamma irradiation and followed intestinal barrier permeability to polyethylene glycol 4000. Addition of Spirulina to the diet led to near-complete normalization of permeability. Feeding phycocyanin extract from Spirulina to rats exposed to x-rays (5 Gy) resulted in the normalization of decreases in dehydrogenase activity, energy-rich phosphate level, and efficiency of antioxidant defense observed in rats without phycocyanin supplementation.\textsuperscript{97}

Implications of the Results of the Studies

There are not many studies in the areas mentioned under this section, nor are the studies as rigorous as those done on immune modulation, anti-cancer/anti-viral effect, and cholesterol-reduction effects. Nevertheless they offer insight into the potential of Spirulina to offer diverse health benefits. These areas deserve more research.

CONCLUSION

Despite the few human studies done so far on the health benefits of Spirulina, the evidence for its potential therapeutic application is overwhelming in the areas of immunomodulation, anti-cancer, anti-viral, and cholesterol-reduction effects. Traditional therapies always rely on the use of natural products and have been the source of information for the discovery of many drugs we have today. Currently, increased cost of health care has become a driving force in the shift towards interest in wellness, self-care, and alternative medicine, and a greater recognition between diet and health care. Spirulina is already in use in these new health care approaches. Further clinical research will help solidify the merit of its use.

Systematic screening for therapeutic substances from algae, particularly cyanobacteria (blue-green algae), has received greater attention recently.\textsuperscript{64, 98} Should therapeutic application be established for it, Spirulina would offer the following unique advantages and possibilities: (1) the technology for mass cultivation and harvest of Spirulina is well-established, (2) Spirulina has undergone two decades of toxicity testing in addition to its known centuries of human use, (3) microbiological and other safety standards have been established for Spirulina products, (4) the two most commonly grown species Spirulina (Arthrospira) platensis and Spirulina (Arthrospira) maxima are free from cyanobacterial toxins and can be grown (under controlled conditions) free of contaminant cyanobacteria by virtue of their adaptation to a highly alkaline environment. Indeed, it is this same property that makes it possible to grow Spirulina in land unsuitable for conventional agriculture, and (5) Spirulina has already been popularized through two decades of commercialization as a food and dietary supplement.

In a similar review article published in the Journal of Applied Phycology in 1993, we called the attention of researchers to further research in the areas of immunomodulation and anti-cancer effects of Spirulina. A comparison of the number of papers reviewed then and now clearly shows the great attention that is being given to research on the potential health benefits of Spirulina. The future holds great promise for more socially and professionally beneficial research. It is hoped that a careful evaluation of the results of the studies summarized above will provide a guide to future research and a basis for current therapeutic use of Spirulina.
REFERENCES


65. Hayashi K, Hayashi T, Morita N. An extract from Spirulina platensis is a selective inhibitor of Herpes simplex virus type 1 penetration into HeLa cells. Phytother Res. 1993;7:76-80.


73. Kato T, Takemoto K, Katayama H, Kuwabara Y. Effects of Spirulina (Spirulina platensis) on dietary hypercho-
JOURNAL OF THE AMERICAN NUTRACEUTICAL ASSOCIATION
A Peer-Reviewed Journal on Nutraceuticals and Nutrition
www.ana-jana.org

EDITOR-IN-CHIEF
Mark Houston, MD – Associate Clinical Professor of Medicine, Vanderbilt University School of Medicine; Director, Hypertension Institute and Vascular Biology, Saint Thomas Medical Group, Saint Thomas Hospital, Nashville, Tennessee.

CO-EDITORS
MEDICINE
Christopher M. Foley, MD – Medical Director, Integrative Care, St. Paul, Minnesota. Serves on the teaching faculty, University of Minnesota, School of Pharmacy.

PHARMACY
Allen M. Kratz, PharmD - Former faculty member at the Philadelphia College of Pharmacy and Science. The first pharmacist appointed to the editorial board of The Merck Manual (12th. edition); co-author of a chapter on Alternative Health Care in REMINGTON: The Science and Practice of Pharmacy (19th. edition).

EDITORIAL BOARD
Jan Basile, MD – Associate Professor of Medicine, Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, South Carolina.

Russell Blaylock, MD – Clinical Assistant Professor, University of Mississippi Medical Center, Jackson, Mississippi.

Jerome B. Block, MD - Professor of Medicine, UCLA School of Medicine. Former Chief, Division of Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California.

Lisa R. Colodny, PharmD, BCNSP - Clinical Coordinator, Broward General Medical Center, Ft. Lauderdale, Florida.

Jeanette Dunn, EdD, RN, CNS - Former Associate Dean of Nursing, University of Tennessee. Co-director, Foundation for Care Management, Vashon, Washington.

Brent Eagan, MD – Professor, Pharmacology and Medicine, Medical University of South Carolina, Charleston, South Carolina.

Clare M. Hasler, PhD - Assistant Professor of Nutrition, Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign.

Ralph G. Hawkins, MD, FRCPC – Associate Professor of Medicine, Division of Nephrology, University of Tennessee-Memphis.

Raja Jaber, MD – Associate Director, University Center for Complementary and Alternative Medicine, Clinical Associate Professor, University of New York at Stony Brook, Stony Brook, New York.

Alexander Mauskop, MD, FAAN – Director, New York Headache Center, and Associate Professor of Clinical Neurology, State University of New York (SUNY), Downstate Medical Center, Brooklyn, New York.

Mark J.S. Miller, PhD - Research Professor and Director of Pediatric Laboratories, Department of Pediatrics, Albany Medical College, Albany, New York.

Lakshmi C. Mishra, MD, PhD – Adjunct Professor, Southern California University of Health Sciences, Whittier, California.

Anthony J. Silvagni, DO, PharmD, MSc, FACOFP - Dean, College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, Florida.

John A. Strupp, MD – Assistant Clinical Professor of Medicine, Vanderbilt University School of Medicine; Chairman, Division of Hematology/Oncology, Saint Thomas Hospital, Nashville, Tennessee.

C. Wayne Weart, PharmD, BCPS, FASHIP - Professor and Chair, Department of Pharmacy Practice, and Associate Professor, Department of Family Medicine, Medical University of South Carolina, Charleston, South Carolina.

Farid Wassef, RPh - Functional medicine practitioner and pharmacist, Stouville, Ontario, Canada; Advisory Board Member, Institute for Functional Medicine.

Bernd Wollschlaeger, MD – Board-certified family practice; Assistant Clinical Professor of Medicine and Family Medicine, University of Miami, School of Medicine.